{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:50:57Z","timestamp":1782802257202,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bulcan.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:25:11Z","timestamp":1734524711000},"page":"149-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing the management of immune-related adverse events and survival in patients with thoracic cancer receiving immunotherapy through artificial intelligence (electronic patient-reported outcomes): The IMPATHI study"],"prefix":"10.1016","volume":"112","author":[{"given":"Serge","family":"Amouin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Parnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Picchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Le Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Barhli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Audisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Brezun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Schernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Vanquaethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-349X","authenticated-orcid":false,"given":"Carole","family":"Helissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2024.11.004_bib0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.bulcan.2024.11.004_bib0145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.bulcan.2024.11.004_bib0150","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"10.1016\/j.bulcan.2024.11.004_bib0155","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10031","key":"10.1016\/j.bulcan.2024.11.004_bib0160","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"10.1016\/j.bulcan.2024.11.004_bib0165","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.004_bib0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"15_suppl.","key":"10.1016\/j.bulcan.2024.11.004_bib0175","doi-asserted-by":"crossref","first-page":"TPS8103","DOI":"10.1200\/jco.2015.33.15_suppl.tps8103","article-title":"KEYNOTE-024: phase III trial of pembrolizumab (MK-3475) vs. platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1)","volume":"33","author":"Brahmer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10066","key":"10.1016\/j.bulcan.2024.11.004_bib0180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.004_bib0185","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2024.11.004_bib0190","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2024.11.004_bib0195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2024.11.004_bib0200","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.11.004_bib0205","first-page":"530","article-title":"Agreement between patient-reported symptoms and their documentation in the medical record","volume":"14","author":"Pakhomov","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.bulcan.2024.11.004_bib0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","author":"US Department of Health and Human Services FDA Center for Biologics Evaluation and Research","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.004_bib0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12652-017-0598-x","article-title":"Remote patient monitoring: a comprehensive study","volume":"10","author":"Malasinghe","year":"2019","journal-title":"J Ambient Intell Humaniz Comput"},{"issue":"5","key":"10.1016\/j.bulcan.2024.11.004_bib0220","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(20)30021-8","article-title":"The increasing value of eHealth in the delivery of patient-centred cancer care","volume":"21","author":"Penedo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.004_bib0225","doi-asserted-by":"crossref","first-page":"e31255","DOI":"10.2196\/31255","article-title":"The use of telemedicine in cancer clinical trials: connect-patient-to-doctor prospective study","volume":"8","author":"Meghiref","year":"2022","journal-title":"JMIR Cancer"},{"key":"10.1016\/j.bulcan.2024.11.004_bib0230","doi-asserted-by":"crossref","first-page":"S1187","DOI":"10.1016\/j.annonc.2021.08.1675","article-title":"1703P Effectiveness of a digital telemonitoring platform for elderly cancer patient (EP) care","volume":"32","author":"Helissey","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2024.11.004_bib0235","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.004_bib0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2024.11.004_bib0245","doi-asserted-by":"crossref","first-page":"105305","DOI":"10.1016\/j.ijmedinf.2023.105305","article-title":"Electronic-PRO Measures for adverse events Of Treatment In ONcology (E-PROMOTION)","volume":"182","author":"Pradhan","year":"2024","journal-title":"Int J Med Inf"},{"issue":"22","key":"10.1016\/j.bulcan.2024.11.004_bib0250","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bulcan.2024.11.004_bib0255","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.bulcan.2024.11.004_bib0260","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2024.11.004_bib0265","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"10.1016\/j.bulcan.2024.11.004_bib0270","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T16:07:41Z","timestamp":1737562061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124004600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0007455124004600"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.11.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the management of immune-related adverse events and survival in patients with thoracic cancer receiving immunotherapy through artificial intelligence (electronic patient-reported outcomes): The IMPATHI study","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}